NeoImmuneTech
Alexandra Wolfarth, PhD, is a Senior Scientist in Translational R&D at NeoImmuneTech since January 2021, previously serving as Scientist in the same department. Alexandra conducted research at Emory University from August 2013 to August 2020 as a PhD student under Dr. Andrew Neish, focusing on the role of commensal bacteria in gut homeostasis. Additionally, Alexandra has experience as a Research Mentor, guiding undergraduate students through experimental design and data analysis, and as a Biology Lab Instructor for undergraduate biology courses. Prior roles include a Research Technician at The University of Arizona, where tasks involved research on allergy and asthma, and a Resident Assistant at Northern Arizona University. Alexandra's educational background includes a PhD in Immunology and Molecular Pathogenesis from Emory University and a Bachelor's degree in Microbiology from Northern Arizona University.
NeoImmuneTech
NeoImmuneTech, Inc. (NIT) is a clinical-stage T cell-focused biopharmaceutical company dedicated to expanding the horizon of immuno-oncology and enhancing immunity to infectious diseases. Our lead drug candidate, NT-I7, is the only clinical-stage long acting rhIL-7, and is uniquely positioned to address unmet medical needs in Immuno-Oncology and Infectious Diseases such as COVID-19. IL-7 is a fundamental cytokine for lymphocyte development, survival, and memory development. Furthermore, NT-I7 has been shown clinically to have desired PK/PD and safety profiles, making it an ideal combination partner with T-cell targeted therapies as well as vaccines. NT-I7 is being studied in multiple clinical trials and many in collaboration with industry leaders in I-O, including Merck, BMS, and Roche for CPI combination trials. Follow us on Twitter @neoimmunetech